Seattle Genetics initiates trial of SEA-TGT for solid tumours

Hodgkin_lymphoma
Seattle Genetics doses the first patient in a Phase I trial of SEA-TGT to treat patients with solid tumours and lymphomas. Credit: Gabriel Caponetti.